Skip to main content
OpenTrials
Completed

NCT Number: NCT01875042

Effect of Transcutaneous Electrostimulation (TENS) on Pain and Physical Function in Patients With Knee Osteoarthritis

The proposed study is a multi-center, randomized, double blind (patient and assessor), sham controlled clinical trial using a parallel 2 group design recruiting 220 patients of at least 18 years of age. The investigators will include patients presenting with clinically and radiologically diagnosed knee OA according to the criteria of the American College of Rheumatology, who experienced knee pain lasting for at least six months, and were diagnosed with radiographic severity of ≥ 2 on the Kellgren-Lawrence grading system or had one or more of the following signs and symptoms in the knee; restricted range of motion, pain in motion, crepitations, morning stiffness. Patients will be randomly allocated to receive TENS or sham TENS for 3 weeks.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Institute of Social and Preventive Medicine (ISPM), University of Bern

Bern, Canton of Bern, 3012, Switzerland

About this study

Background

Osteoarthritis (OA) is the most common arthritic condition, which is one of the leading causes of disability in adults. Currently, no treatment can stop or reverse the progressive joint degeneration caused by OA. Most clinical interventions aim to improve pain and physical function. Transcutaneous electrical nerve stimulation (TENS) is widely used in the management of knee OA to relieve osteoarthritic pain and facilitate the performance of therapeutic activities in order to maintain or improve physical function. Although its use is widespread, the available evidence is of questionable quality. An adequately sized and well conducted randomized controlled trial (RCT) investigating the effectiveness and safety of TENS as treatment modality for knee OA is warranted to assist clinicians and policy makers to make decisions that are based on high-quality evidence, ultimately optimizing delivery of health-care in knee OA.

Objective

To determine TENS safety and effectiveness on pain and physical function compared to sham TENS in patients with knee OA.

Methods

Multi-center, randomized, double blind (patient and assessor), sham controlled clinical trial using a parallel 2 group design. Patients will be randomly allocated to receive TENS or sham TENS for 3 weeks. Informed consent of eligible patients will be obtained prior to randomization. Patients will be assigned on a 1:1 basis to the TENS or sham TENS group. Randomization will be centralized using randomization software and an electronic randomization form, generated by the trial coordinating centre (CTU Bern). Patients will be randomized once demographic data and selection criteria are completed by the recruiting physician in an electronic form. Randomization will be stratified according to treatment centre, TENS naivety and clinical severity.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men and women of at least 18 years of age
  • Clinical or radiological diagnosis of knee OA according to the criteria of the American College of Rheumatology
  • Knee pain lasting for six months or longer
  • Radiographic evidence of at least one osteophyte at the tibiofemoral joint (Kellgren-Lawrence grade ≥ 2) or one or more of the following signs and symptoms in the knee; restricted range of motion, pain in motion, crepitations, morning stiffness
  • Written informed consent

Exclusion criteria

  • Patients diagnosed with rheumatoid arthritis or other musculoskeletal diseases affecting lower extremities
  • Relevant effusion in the index knee
  • Known current or remittent cancer
  • Carry cardiac pacemaker or defibrillator in situ
  • Knee surgery in previous 6 months
  • Received treatment with arthrocentesis
  • Intra-articular injection of steroids in previous 3 months
  • Inability to understand instructions or to give informed consent

Treatment and study plan

TENS

Device

Transcutaneous electrical nerve stimulation

SHAM TENS

Device

Sham Transcutaneous electrical nerve stimulation

Primary outcomes

  1. WOMAC pain subscale

    Time frame: End of treatment (at 3 weeks)

Secondary outcomes

  1. WOMAC global subscale

    Time frame: Baseline, end of treatment (at 3 weeks), 3-month follow-up

  2. WOMAC physical function subscale

    Time frame: Baseline, end of treatment (at 3 weeks), 3-month follow-up

  3. Overall pain measured on VAS

    Time frame: Baseline, end of treatment (at 3 weeks), 3-month follow-up

  4. Hospital anxiety and depression scale

    Time frame: Baseline, end of treatment (at 3 weeks), 3-month follow-up

  5. Aberdeen measure of participation

    Time frame: Baseline, end of treatment (at 3 weeks), 3-month follow-up

  6. Mean analgesic intake per patient

    Time frame: Baseline, end of treatment (at 3 weeks), 3-month follow-up

  7. Number of drop-outs because of adverse events

    Time frame: End of treatment (at 3 weeks), 3-month follow-up

  8. Number of patients experiencing local adverse events

    Time frame: End of treatment (at 3 weeks), 3-month follow-up

  9. Number of patients experiencing any side effects

    Time frame: End of treatment (at 3 weeks), 3-month follow-up

  10. Number of patients experiencing serious side effects

    Time frame: End of treatment (at 3 weeks), 3-month follow-up

  11. Number of drop-outs

    Time frame: End of treatment (at 3 weeks), 3-month follow-up

  12. WOMAC pain subscale

    Time frame: Baseline, third treatment session, 3-month follow-up

Sponsors and collaborators

Lead sponsor

Insel Gruppe AG, University Hospital Bern

Other

Collaborators

  • Arco Foundation

Registry information

Official study title

Does Transcutaneous Electrical Nerve Stimulation (TENS) Affect Pain and Function in Patients With Osteoarthritis of the Knee? ETRELKA, a Randomised Controlled Trial

Acronym: ETRELKA

Important dates

Study start
2012
Primary completion
2014
Study completion
2015
First posted
Jun 11, 2013
Registry last updated
Apr 12, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.